ACS Pharmacology & Translational Science is planning to publish a Special Issue titled “Advances in GPCR Signal Transduction” in April 2020. Guest Editors for the Special Issue will be Dr. Sophie Bradley, LKAS Fellow, and Professor Andrew Tobin, professor of molecular pharmacology, both of the Institute of Molecular Cell & Systems Biology, University of Glasgow, Scotland. Dr. Bradley and Professor Tobin will compile the Special Issue in collaboration with the European Research Network on Signal Transduction (ERNEST). Together with ACS Pharmacology & Translational Science Editor-in-Chief Patrick M. Sexton, they invite everyone conducting research in this area to submit a manuscript by January 15, 2020.
“This is an ideal opportunity for researchers across the field of GPCR signal transduction to present original perspectives and concepts in this fast moving area of research,” says Professor Tobin.
“We are delighted to partner with ACS Pharmacology & Translational Science in this special issue that presents an opportunity to express the vision and views of members of the ERNEST collaborative network. Our contributions alongside those from other leading international scientists will make for an exciting and provocative publication,” says Dr. Martha Sommer, Chair of ERNEST.
What to Submit—Deadline: January 15, 2020
Articles, Letters, Reviews, Perspectives, Drug Discovery Stories, and Viewpoints are all welcome for possible inclusion in this Special Issue. For details on requirements for each manuscript type, please consult the Author Guidelines. You can also find the entire ACS Pharmacology & Translational Science scope below.
Areas of particular interest include:
- Multi-modal GPCR signalling
- Signalling bias
- Allosteric modulation
- GPCR phosphorylation
- Pathophysiological GPCR processes
- Targeting GPCRs in human disease
- Structural basis of GPCR signal transduction
ACS Pharmacology & Translational Science Scope
ACS Pharmacology & Translational Science publishes high-quality, innovative research across the broad spectrum of biological sciences —from basic and molecular sciences to translational pre-clinical studies. Its editors also consider clinical studies that address novel mechanisms of action and methodological papers that provide innovation, and advance translation.
The journal’s editors give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest, but they will consider all innovative research with articulated translational relevance.
ACS Pharmacology and Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition.